V Köllner1,2, K Bernardy3, W Greiner4, L Krumbein5, H Lucius6, M Offenbächer7, M Sarholz8, M Settan9, W Häuser10,11. 1. Abteilung für Psychosomatische Medizin und Verhaltenstherapie, Rehazentrum Seehof der Deutschen Rentenversicherung Bund, Teltow, Deutschland. koellner@psychosoma.de. 2. Forschungsgruppe Psychosomatische Rehabilitation, Charité - Universitätsmedizin Berlin, Berlin, Deutschland. koellner@psychosoma.de. 3. Abteilung für Schmerztherapie, Berufsgenossenschaftliches Universitätsklinikum Bergmannsheil gGmbH, Ruhr-Universität Bochum, Bochum, Deutschland. 4. Psychosomatische und Psychoonkologische Tagesklinik, Universitätsklinikum Jena, Jena, Deutschland. 5. Rehabilitationsklinik Bad Säckingen, Bad Säckingen, Deutschland. 6. Schmerzambulanz, Helios-Fachklinik Schleswig, Schleswig, Deutschland. 7. Institut für Allgemeinmedizin, Klinikum der Universität München, Campus Innenstadt, München, Deutschland. 8. St. Josefs Klinik, Rheumazentrum Ruhrgebiet, Herne, Deutschland. 9. Deutsche Fibromyalgie Vereinigung, Seckach, Deutschland. 10. Innere Medizin I, Klinikum Saarbrücken gGmbH, Saarbrücken, Deutschland. 11. Klinik und Poliklinik für Psychosomatische Medizin und Psychotherapie, Technische Universität München, München, Deutschland.
Abstract
BACKGROUND: The regular update of the guidelines on fibromyalgia syndrome, AWMF number 145/004, was scheduled for April 2017. METHODS: The guidelines were developed by 13 scientific societies and 2 patient self-help organizations coordinated by the German Pain Society. Working groups (n =8) with a total of 42 members were formed balanced with respect to gender, medical expertise, position in the medical or scientific hierarchy and potential conflicts of interest. A systematic search of the literature for systematic reviews of randomized, controlled studies on psychological and psychotherapeutic procedures from December 2010 to May 2016 was performed in the Cochrane library, MEDLINE, PsycINFO and Scopus databases. Levels of evidence were assigned according to the classification system of the Oxford Centre for Evidence-Based Medicine version 2009. The strength of recommendations was achieved by multiple step formalized procedures to reach a consensus. Efficacy, risks, patient preferences and applicability of available therapies were weighed up against each other. The guidelines were reviewed and approved by the board of directors of the societies engaged in the development of the guidelines. RESULTS AND CONCLUSION: Cognitive behavioral therapies received a strong recommendation but biofeedback, guided imagery and hypnosis received a weak recommendation.
BACKGROUND: The regular update of the guidelines on fibromyalgia syndrome, AWMF number 145/004, was scheduled for April 2017. METHODS: The guidelines were developed by 13 scientific societies and 2 patient self-help organizations coordinated by the German Pain Society. Working groups (n =8) with a total of 42 members were formed balanced with respect to gender, medical expertise, position in the medical or scientific hierarchy and potential conflicts of interest. A systematic search of the literature for systematic reviews of randomized, controlled studies on psychological and psychotherapeutic procedures from December 2010 to May 2016 was performed in the Cochrane library, MEDLINE, PsycINFO and Scopus databases. Levels of evidence were assigned according to the classification system of the Oxford Centre for Evidence-Based Medicine version 2009. The strength of recommendations was achieved by multiple step formalized procedures to reach a consensus. Efficacy, risks, patient preferences and applicability of available therapies were weighed up against each other. The guidelines were reviewed and approved by the board of directors of the societies engaged in the development of the guidelines. RESULTS AND CONCLUSION: Cognitive behavioral therapies received a strong recommendation but biofeedback, guided imagery and hypnosis received a weak recommendation.
Authors: F Petzke; W Brückle; U Eidmann; P Heldmann; V Köllner; T Kühn; H Kühn-Becker; M Strunk-Richter; M Schiltenwolf; M Settan; M von Wachter; M Weigl; W Häuser Journal: Schmerz Date: 2017-06 Impact factor: 1.107
Authors: J Langhorst; P Heldmann; P Henningsen; K Kopke; L Krumbein; H Lucius; A Winkelmann; B Wolf; W Häuser Journal: Schmerz Date: 2017-06 Impact factor: 1.107